HRP20000162B1 - Amorphous torasemide modification - Google Patents
Amorphous torasemide modificationInfo
- Publication number
- HRP20000162B1 HRP20000162B1 HR20000162A HRP20000162A HRP20000162B1 HR P20000162 B1 HRP20000162 B1 HR P20000162B1 HR 20000162 A HR20000162 A HR 20000162A HR P20000162 A HRP20000162 A HR P20000162A HR P20000162 B1 HRP20000162 B1 HR P20000162B1
- Authority
- HR
- Croatia
- Prior art keywords
- torasemide modification
- amorphous torasemide
- amorphous
- modification
- torasemide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (30)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20000162A HRP20000162B1 (en) | 2000-03-20 | 2000-03-20 | Amorphous torasemide modification |
ARP000102019A AR023788A1 (es) | 2000-03-20 | 2000-04-28 | Modificacion amorfa de torasemida |
KR1020027012411A KR20020093847A (ko) | 2000-03-20 | 2000-05-02 | 무정형 토라세미드 변형물 |
PCT/HR2000/000011 WO2001070694A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
BR0017175-1A BR0017175A (pt) | 2000-03-20 | 2000-05-02 | Modificação da torasemida amorfa |
PT00920938T PT1272470E (pt) | 2000-03-20 | 2000-05-02 | Forma modificada da torasemida amorfa |
PL00357154A PL357154A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
EEP200200534A EE200200534A (et) | 2000-03-20 | 2000-05-02 | Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat |
DE60007360T DE60007360T2 (de) | 2000-03-20 | 2000-05-02 | Amorphe modifikation von torasemid |
HU0300596A HUP0300596A3 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification, process for its preparation its use and pharmaceutical compositions containing it |
SK1509-2002A SK15092002A3 (sk) | 2000-03-20 | 2000-05-02 | Amorfná modifikácia torasemidu, spôsob jej prípravy a farmaceutický prostriedok obsahujúci túto modifikáciu |
EA200201003A EA004950B1 (ru) | 2000-03-20 | 2000-05-02 | Аморфная модификация торасемида |
AU2000241348A AU2000241348A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
EP00920938A EP1272470B1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
GE4937A GEP20043300B (en) | 2000-03-20 | 2000-05-02 | Amorphous Torasemide Modification |
ES00920938T ES2213006T3 (es) | 2000-03-20 | 2000-05-02 | Forma modificada de torasemida amorfa. |
US10/239,024 US6767917B1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
CZ20023436A CZ20023436A3 (cs) | 2000-03-20 | 2000-05-02 | Amorfní modifikace torasemidu, způsob její přípravy a přípravy farmaceutického prostředku obsahujícího tuto modifikaci |
IL15180100A IL151801A0 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
JP2001568906A JP2003528083A (ja) | 2000-03-20 | 2000-05-02 | 非晶質トラセミド変態 |
MXPA02009210A MXPA02009210A (es) | 2000-03-20 | 2000-05-02 | Modificacion amorfa de torasemida. |
CA002401908A CA2401908A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
YU70502A YU70502A (sh) | 2000-03-20 | 2000-05-02 | Amorfna modifikacija torasemida |
CNB008194319A CN1211368C (zh) | 2000-03-20 | 2000-05-02 | 无定形的托拉塞米变体 |
AT00920938T ATE256662T1 (de) | 2000-03-20 | 2000-05-02 | Amorphe modifikation von torasemid |
SI200030301T SI1272470T1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
IS6551A IS6551A (is) | 2000-03-20 | 2002-09-17 | Formlaus torasemíð umbreyting |
NO20024464A NO20024464L (no) | 2000-03-20 | 2002-09-18 | Amorf Torasemide-modifikasjon |
ZA200208309A ZA200208309B (en) | 2000-03-20 | 2002-10-15 | Amorphous torasemide modification. |
BG107208A BG107208A (en) | 2000-03-20 | 2002-10-21 | Amorphous torasemide modification |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20000162A HRP20000162B1 (en) | 2000-03-20 | 2000-03-20 | Amorphous torasemide modification |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20000162A2 HRP20000162A2 (en) | 2001-12-31 |
HRP20000162B1 true HRP20000162B1 (en) | 2004-06-30 |
Family
ID=10947070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000162A HRP20000162B1 (en) | 2000-03-20 | 2000-03-20 | Amorphous torasemide modification |
Country Status (29)
Country | Link |
---|---|
US (1) | US6767917B1 (pt) |
EP (1) | EP1272470B1 (pt) |
JP (1) | JP2003528083A (pt) |
KR (1) | KR20020093847A (pt) |
CN (1) | CN1211368C (pt) |
AR (1) | AR023788A1 (pt) |
AT (1) | ATE256662T1 (pt) |
AU (1) | AU2000241348A1 (pt) |
BG (1) | BG107208A (pt) |
BR (1) | BR0017175A (pt) |
CA (1) | CA2401908A1 (pt) |
CZ (1) | CZ20023436A3 (pt) |
DE (1) | DE60007360T2 (pt) |
EA (1) | EA004950B1 (pt) |
EE (1) | EE200200534A (pt) |
ES (1) | ES2213006T3 (pt) |
GE (1) | GEP20043300B (pt) |
HR (1) | HRP20000162B1 (pt) |
HU (1) | HUP0300596A3 (pt) |
IL (1) | IL151801A0 (pt) |
IS (1) | IS6551A (pt) |
MX (1) | MXPA02009210A (pt) |
NO (1) | NO20024464L (pt) |
PL (1) | PL357154A1 (pt) |
PT (1) | PT1272470E (pt) |
SK (1) | SK15092002A3 (pt) |
WO (1) | WO2001070694A1 (pt) |
YU (1) | YU70502A (pt) |
ZA (1) | ZA200208309B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465496B1 (en) * | 1999-08-11 | 2002-10-15 | Teva Pharmaceutical Industries, Ltd. | Torsemide polymorphs |
IN192178B (pt) | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
CA2536967A1 (en) | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
JP2008531579A (ja) | 2005-02-24 | 2008-08-14 | ニトロメッド インコーポレーティッド | 酸化窒素増強利尿化合物、組成物および使用方法 |
CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
US6096779A (en) * | 1995-02-22 | 2000-08-01 | Hoechst Pharmaceuticals & Chemicals K.K. | Amorphous piretanide, piretanide polymorphs, process for their preparation and their use |
IN182496B (pt) | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
US6465496B1 (en) | 1999-08-11 | 2002-10-15 | Teva Pharmaceutical Industries, Ltd. | Torsemide polymorphs |
-
2000
- 2000-03-20 HR HR20000162A patent/HRP20000162B1/xx not_active IP Right Cessation
- 2000-04-28 AR ARP000102019A patent/AR023788A1/es unknown
- 2000-05-02 MX MXPA02009210A patent/MXPA02009210A/es unknown
- 2000-05-02 JP JP2001568906A patent/JP2003528083A/ja active Pending
- 2000-05-02 GE GE4937A patent/GEP20043300B/en unknown
- 2000-05-02 AU AU2000241348A patent/AU2000241348A1/en not_active Abandoned
- 2000-05-02 EA EA200201003A patent/EA004950B1/ru not_active IP Right Cessation
- 2000-05-02 EE EEP200200534A patent/EE200200534A/xx unknown
- 2000-05-02 SK SK1509-2002A patent/SK15092002A3/sk unknown
- 2000-05-02 WO PCT/HR2000/000011 patent/WO2001070694A1/en not_active Application Discontinuation
- 2000-05-02 ES ES00920938T patent/ES2213006T3/es not_active Expired - Lifetime
- 2000-05-02 CZ CZ20023436A patent/CZ20023436A3/cs unknown
- 2000-05-02 BR BR0017175-1A patent/BR0017175A/pt not_active IP Right Cessation
- 2000-05-02 US US10/239,024 patent/US6767917B1/en not_active Expired - Fee Related
- 2000-05-02 CN CNB008194319A patent/CN1211368C/zh not_active Expired - Fee Related
- 2000-05-02 CA CA002401908A patent/CA2401908A1/en not_active Abandoned
- 2000-05-02 AT AT00920938T patent/ATE256662T1/de not_active IP Right Cessation
- 2000-05-02 YU YU70502A patent/YU70502A/sh unknown
- 2000-05-02 PT PT00920938T patent/PT1272470E/pt unknown
- 2000-05-02 DE DE60007360T patent/DE60007360T2/de not_active Expired - Fee Related
- 2000-05-02 EP EP00920938A patent/EP1272470B1/en not_active Expired - Lifetime
- 2000-05-02 HU HU0300596A patent/HUP0300596A3/hu unknown
- 2000-05-02 KR KR1020027012411A patent/KR20020093847A/ko not_active Application Discontinuation
- 2000-05-02 PL PL00357154A patent/PL357154A1/xx not_active Application Discontinuation
- 2000-05-02 IL IL15180100A patent/IL151801A0/xx unknown
-
2002
- 2002-09-17 IS IS6551A patent/IS6551A/is unknown
- 2002-09-18 NO NO20024464A patent/NO20024464L/no not_active Application Discontinuation
- 2002-10-15 ZA ZA200208309A patent/ZA200208309B/en unknown
- 2002-10-21 BG BG107208A patent/BG107208A/xx active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0011749D0 (en) | Light-eminating devices | |
GB0015716D0 (en) | Devices | |
AU3391801A (en) | Pyridinylimidazoles | |
IL151020A0 (en) | Substituted arylpyrazines | |
AU8274301A (en) | Electro-powder | |
AU6227101A (en) | Substituted iminoazines | |
AU6803901A (en) | Bis-arylsulfones | |
AU5825501A (en) | Substituted benzoylcyclohexenones | |
PL358119A1 (en) | Substituted phenyluracils | |
AU6619001A (en) | Liquid-pourers | |
IL151801A0 (en) | Amorphous torasemide modification | |
AU9187601A (en) | Triazolo-epothilones | |
AU4686401A (en) | Hypotensors | |
AU3521202A (en) | Application devices | |
AU4831301A (en) | Gm-negative ehv-mutants | |
AU8756801A (en) | Thienopyrrolidinones | |
AU2360402A (en) | Substituted phenyluracils | |
SI1272470T1 (en) | Amorphous torasemide modification | |
IL154457A0 (en) | Mircronized torsemide | |
GB0028423D0 (en) | Eductional aid | |
GB0028494D0 (en) | Tassel-making aid | |
AU1702P (en) | Trailblazer Xanthostemon chrysanthus | |
AU1852P (en) | Tickit xTriticosecale | |
AU2117P (en) | Gauka Gaura lindheimeri | |
TW452154U (en) | Improved magnetic-sensing device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090219 Year of fee payment: 10 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20100321 |